Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amarin ( (AMRN) ) has issued an announcement.
On March 25, 2026, Amarin’s board moved to streamline its governance structure by reducing the size of the board from nine to seven directors, following notice from Dr. Paul Cohen and Oliver O’Connor that they would not stand for re-election and would resign immediately before the 2026 Annual Meeting of Shareholders, with the company stating there were no disagreements related to operations, policies, or practices. On the same date, the board revised its non-employee director compensation policy to provide annual equity awards in the form of restricted stock units and options that vest after one year or at the next annual meeting, while noting that if shareholders do not approve key proposals at the 2026 meeting, directors will be unable to receive these equity awards and the board will need to consider alternative cash-based compensation.
The most recent analyst rating on (AMRN) stock is a Sell with a $15.50 price target. To see the full list of analyst forecasts on Amarin stock, see the AMRN Stock Forecast page.
Spark’s Take on AMRN Stock
According to Spark, TipRanks’ AI Analyst, AMRN is a Neutral.
The score is held down primarily by weak financial performance (shrinking revenue, ongoing losses, and inconsistent/weak cash flow) and bearish technicals (below key moving averages with negative MACD). The latest earnings call provides partial support via cost-cutting progress, positive operating cash flow in 2025, strong liquidity/no debt, and partnership upside, but revenue pressure and variability keep overall risk elevated.
To see Spark’s full report on AMRN stock, click here.
More about Amarin
Amarin Corporation plc operates in the biopharmaceutical industry, with a focus on developing and commercializing therapeutics, particularly in cardiovascular and related metabolic diseases. The company’s strategy emphasizes prescription-based products and seeks to align its governance and board structure with shareholder interests and evolving corporate governance standards.
Average Trading Volume: 87,276
Technical Sentiment Signal: Sell
Current Market Cap: $305.3M
For a thorough assessment of AMRN stock, go to TipRanks’ Stock Analysis page.